The role of IGF-1 and the distribution of body fat in decreasing the number of prostate rebiopsies
Autores de IIS La Fe
Grupos
Abstract
Objective: To assess the usefulness of IGF-1 and internal organ fat measured by bioelectrical impedance audiometry to avoid rebiopsies in patients with persistently high prostate-specific antigen (PSA) levels. Material and method: A prospective study was conducted with 92 patients who underwent prostate rebiopsy due to high PSA levels with negative results in the rectal examination and a lack of preneoplastic lesions. The patients previously had their IGF-1 levels measured and had undergone an impedance audiometry test using the abdominal Fat Analyser AB-140 TANITA system. We calculated the receiver operating characteristic (ROC) curves for the PSA levels, %PSA, internal organ fat and IGF-1 and PSA density. Results: Twenty-five patients were diagnosed with prostate cancer. These patients had significantly higher PSA, PSAd and IGF-1 values and a tendency towards higher internal organ fat levels and lower %PSA readings (p=.001, p=.003, p=.001, p=.24 and P=0.28, respectively). The ROC curve showed an area under the curve for IGF-1 and PSA of .82 and .81, respectively. Using the cutoff points for 95% sensitivity and using the 3 criteria as an indication of rebiopsy, 74% of the biopsies would have been spared, leaving undiagnosed only 1 patient with clinically significant cancer -Gleason score > 7 (4 + 3)-. The positive and negative predictive values for the set of variables were higher than for each one separately (PPV: 66/NPV: 63). The cost of both determinations was 82 euros. Conclusions: Our results suggest that measuring IGF-1 could significantly decrease the number of unnecessary rebiopsies in an inexpensive and safe manner. (C) 2016 AEU.
Datos de la publicación
- ISSN/ISSNe:
- 0210-4806, 1699-7980
- Tipo:
- Article
- Páginas:
- 82-87
- Factor de Impacto:
- 0,344 SCImago ℠
- Cuartil:
- Q3 SCImago ℠
ACTAS UROLOGICAS ESPANOLAS ENE EDICIONES SL
Citas Recibidas en Web of Science: 1
Documentos
- No hay documentos
Filiaciones
Keywords
- insuline growth; factor-1; Obesity; Rebiopsy; Prostate cancer
Proyectos asociados
PROSPET. DISPOSITIVO MULTI-IMAGEN CON UN DETECTOR PET PARA GUIAR LA BIOPSIA, EL TRATAMIENTO Y EL SEGUIMIENTO DEL CÁNCER DE PRÓSTATA.
Investigador Principal: CÉSAR DAVID VERA DONOSO
DTS15/00044 . INSTITUTO DE SALUD CARLOS III . 2016
ESTUDIO FASE III, MULTICENTRICO, ALEATORIZADO, DOBLE CIEGO DE 48 SEMANAS, CON UN PERIDO INICIAL DE 12 SEMANAS CONTROLADO CON PLACEBO, PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE OSILODROSTAT EN PACIENTES CON ENFERMEDADES DE CUSHING.
Investigador Principal: ROSA CÁMARA GÓMEZ
CLCI699C2302 . 2016
ESTUDIO SOBRE PRÁCTICA CLÍNICA HABITUAL EN PACIENTES CON SÍNDROME DE DOLOR VESICAL (SDV) EN UNIDADES DE UROLOGÍA FUNCIONAL Y URODINÁMICA.
Investigador Principal: SALVADOR ARLANDIS GUZMÁN
AST-URO-13-02 . 2014
ESTUDIO OBSERVACIONAL, TRASVERSAL Y MULTICÉNTRICO PARA VALORAR EL CUMPLIMENTO TERAPÉUTICO CON SOMAVERT® EN PACIENTES CON ACROMEGALIA EN CONDICIONES DE PRÁCTICA CLÍNICA HABITUAL.
Investigador Principal: ROSA CÁMARA GÓMEZ
PFI-PEG-2014-01 . 2015
IMPLEMENTACION DE UN CUESTIONARIO RAPIDO COMO HERRAMIENTA PARA IDENTIFICAR A VARONES . 50 ANOS A LOS QUE SE LES DEBERIA EVALUAR HIPERPLASIA BENIGNA DE PROSTATA QUE ACUDEN A ATENCION PRIMARIA CON OTRAS CO-MORBILIDADES.
Investigador Principal: ALBERTO BUDÍA ALBA
FDC116114
ESTUDIO OBSERVACIONAL, MULTICÉNTRICO INTERNACIONAL, PARA EVALUAR LA EFECTIVIDAD EN LA PRÁCTICA CLÍNICA COTIDIANA DE LA LANREOTIDA AUTOGEL 120 MG, EN INTERVALOS POSOLÓGICOS PROLONGADOS (>4 SEMANAS), PARA EL TRATAMIENTO DE LA ACROMEGALIA: ESTUDIO SOMACROL.
Investigador Principal: ROSA CÁMARA GÓMEZ
IPS-SOM-2015-01 . 2016
ESTUDIO MUNDIAL SOBRE EL CONTROL Y LAS COMPLICACIONES DEL HIPOTITUITARISMO (HYPOCCS).
Investigador Principal: JUAN FRANCISCO MERINO TORRES
B9R-MC-GDGA . 2011
Cita
Moran E,Martinez M,Budia A,Broseta E,Camara R,Boronat F. The role of IGF-1 and the distribution of body fat in decreasing the number of prostate rebiopsies. Actas Urol Esp. 2017. 41. (2):p. 82-87. IF:1,260. (4).